WO2007148755A1 - 新規アミロイド親和性化合物 - Google Patents
新規アミロイド親和性化合物 Download PDFInfo
- Publication number
- WO2007148755A1 WO2007148755A1 PCT/JP2007/062503 JP2007062503W WO2007148755A1 WO 2007148755 A1 WO2007148755 A1 WO 2007148755A1 JP 2007062503 W JP2007062503 W JP 2007062503W WO 2007148755 A1 WO2007148755 A1 WO 2007148755A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- compound
- pyridine
- salt
- amyloid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Definitions
- the present invention relates to a compound used for diagnosis of head degenerative diseases. More specifically, the present invention relates to a compound useful for detection of amyloid at a lesion site in the diagnosis of diseases in which amyloid accumulates such as Alzheimer's disease.
- amyloidosis Diseases that develop when fibrous proteins called amyloid are deposited in various organs or tissues in the body are collectively called amyloidosis.
- a common feature of amyloidosis is that fibrillar protein called amyloid rich in ⁇ -sheet structure is deposited in various organs or regions throughout the body, causing functional abnormalities in the organs and tissues.
- AD and RE Alzheimer's disease
- AD and RE which is a typical disease of amyloidosis
- AD and RE is known as a disease causing dementia. Since this disease is a disease in which amyloid gradually deposits in the brain and causes death, it can be said that this disease has a higher social interest than other amyloidosis.
- AD and RE Alzheimer's disease
- AD is characterized by three intracerebral pathological findings: appearance of senile plaques, neurofibrillary tangles and extensive neuronal loss.
- Senile plaques are structures with amyloid as the main component, and their appearance is considered to be the first stage of AD development, that is, a pathological finding in the brain that appears more than 10 years before the appearance of clinical symptoms.
- Diagnosis of AD is performed by performing various cognitive function evaluations (for example, Hasegawa scale, ADAS_JCog, MMSE, etc.) after supplementarily combining image diagnosis such as CT and MRI. Yes.
- various cognitive function evaluations for example, Hasegawa scale, ADAS_JCog, MMSE, etc.
- image diagnosis such as CT and MRI.
- amyloid composing senile plaques is an aggregate of amyloid protein (hereinafter referred to as A), and further, the aggregate of A has a ⁇ sheet structure, thereby causing neurocytotoxicity. Many studies have reported this. Based on these findings, the so-called “amyloid cascade hypothesis” has been proposed, in which the deposition of ⁇ / 3 in the brain triggers the formation of neurofibrillary tangles and neuronal loss as downstream phenomena ( Non-patent literature 2).
- Non-patent Document 10 There have been reports of compounds labeled with 11 C and radioactive halogens such as [1,2, _a] pyridine (hereinafter referred to as IMPY) and imidazopyridine derivatives (Patent Document 3, Non-Patent Document 9).
- IMPY radioactive halogens
- Patent Document 9 imidazopyridine derivatives
- some of these diagnostic imaging probes have undergone human imaging studies and may show radioactive accumulation in the brain that is clearly different from normal cases in AD patients. It has been reported (Non-patent document 10, Non-patent document 11).
- Patent Document 1 Japanese Translation of Special Publication 2004—506723
- Patent Document 2 JP 2005-504055 gazette
- Patent Document 3 Special Table 2005-512945
- Patent Document 4 Japanese Translation of Special Publication 2002-523383
- Non-Patent Document 1 J. A. Hardy & G. A. Higgins, Alzheimer's Disease: The Amyloid Cascade Hypohesis., Science, 1992, 256, p.184-185
- Non-Patent Document 2 G. McKhann et al "" Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease., Neurology, 1984, 34, p.9 39-944
- Non-Patent Document 3 Z.-P. Zhuang et al "" Radioiodinated Styrylbenzenes and Thioflavins a s Probes for Amyloid Aggregates. ", J. Med. Chem., 2001, 44, p.1905-1914
- Non-Special Reference 5 H. F. Kung et al, "Novel Stilbenes as Probes for amyloid plaques., J. American Chemical Society, 2001, 123, p.12740-12741
- Non-Patent Document 6 Zhi_Ping Zhuang et al., "IBOX (2- (4'-dimethylaminophenyl) -6- iodob ensoxazole): a ligand for imaging amyloid plaques in the brain., Nuclear Medicine a nd Biology, 2001, 28, p.887- 894
- Non-Patent Document 7 Furumoto Y et al "" [11C] BF- 227: A New 11C- Labeled 2-Ethenylbe nzoxazole Derivative for Amyloid- ⁇ Plaques Imaging., European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, Sup. L, P759
- Patent Document 8 Eric D. Agdeppa et al, "2-Dialkylamino-6-Acylmalononitrile Substitu ted Naphthalenes (DDNP Analogs): Novel Diagnostic and Therapeutic Tools in Alzh eimer's Disease.”, Molecular Imaging and Biology, 2003, 5 , P.404-417
- Patent Document 9 Zhi— Ping Zhuang et al., “Structure— Activity Relationship of Imidazo [l , 2-a] pyridines as Ligands for Detecting ⁇ -Amyloid Plaques in the Brain. ", J. Med. Chem, 2003, 46, p.237-243
- Non-Patent Document 10 W. E. Klunk et al., "Imaging brain amyloid in Alzheumer's disease w ith Pittsburgh Compound-B.”, Ann. Neurol., 2004, 55, p.306-319
- Patent Document 11 Nicolaas P. L. G. VerhoefF et al "" In- Vivo Imaging of Alzheimer Dis ease ⁇ -Amyloid With [11C] SB-13 PET., American Journal of Geriatric Psychiatry, 2004, 12, p.584-595
- the compound labeled with SB-13 with ["C] may have a clearance from normal tissues in experiments using rats. The force shown The clearance speed is not fast enough (Masahiro Ono et al., Nuclear Medicine and Biology, 2003, 30, ⁇ ⁇ 565_571).
- IMPY and other compounds having an imidazopyridine skeleton have the following properties when they migrate into the brain after administration and accumulate in amyloid. Unlike the compounds described above, clearance from normal tissues to have excellent properties such as fast, there is a clear result of the experiments with [12 3 ⁇ 4 Hyoshikyi ⁇ compound. However, IMPY is a compound that shows a positive result in a reverse mutation test, and in order to use this compound as an imaging diagnostic probe, it is necessary to pay sufficient attention to its dosage and dosage form. (International Publication No. 03/106439 Issue pamphlet)
- the present invention has been made in view of the above circumstances, and has a compound having affinity for amyloid, sufficiently high clearance from normal tissue, and reduced toxicity such as mutagenicity. Aimed to obtain.
- the inventor has found that a compound group satisfying the above conditions can be obtained by using a compound having an imidazopyridine phenyl skeleton, in which oxygen is bonded to carbon of the phenyl group. Was completed.
- R 1 is hydrogen, a hydroxyl group, a carboxyl group, a sulfate group, an amino group, a nitro group, a cyano group, an alkyl substituent having 1 to 4 carbon atoms, or an alkoxy substituent having 1 to 4 carbon atoms. More arbitrary groups can be selected. R 1 is more preferably a hydroxyl group, a methyl substituent, or a methoxy substituent, preferably a hydroxyl group, an alkyl substituent having 1 to 4 carbon atoms, or an alkoxy substituent having 1 to 4 carbon atoms. Masle.
- R 2 can be any radioactive halogen substituent, 18 F, 76 Br, 123 I, 124 I, 125 I or 131 preferably be used a halogen selected from I instrument 18 F, 76 Select from Br, 123 1 or 125 1 It is more preferred to use a halogen, which is particularly preferred.
- M is an integer of 0-2.
- amyloid deposits comprising the compound represented by the formula (1) or a salt thereof and a pharmaceutically acceptable carrier or excipient.
- a pharmaceutical composition for in vivo imaging is provided.
- a compound represented by the formula (1) or a salt thereof for use in in vivo imaging of amyloid deposition there is provided a compound represented by the formula (1) or a salt thereof for use in in vivo imaging of amyloid deposition.
- the step (b) is performed by PET or SPECT imaging.
- R 3 is hydrogen, a hydroxyl group, a carboxyl group, a sulfate group, an amino group, a nitro group, a cyano group, an alkyl substituent having 1 to 4 carbon atoms, or an alkoxy substituent having 1 to 4 carbon atoms. More arbitrary groups can be selected. R 3 is more preferably a hydroxyl group, a methyl substituent, or a methoxy substituent, preferably a hydroxyl group, an alkyl substituent having 1 to 4 carbon atoms, or an alkoxy substituent having 1 to 4 carbon atoms. Masle.
- R 4 may be a group selected from a non-radioactive halogen substituent, a methanesulfonic acid substituent, a trifluoromethanesulfonic acid substituent, or an aromatic sulfonic acid substituent.
- a non-radioactive halogen substituent a halogen that can be a target in a nucleophilic substitution reaction using radioactive fluorine can be used, and preferably iodine or bromine can be used.
- M is an integer of 0-2.
- reaction conditions at this time can be carried out according to a conventional method, for example, a method described in literature (King, L. Carroll and Ostrum, G. Kenneth, Journal of Organic Chemistry, 1964, 29 (12), p. 3459_3461).
- the amount of the solvent used is sufficient if it is sufficient for the reaction. However, if it is too much, it is impossible to obtain a precipitate of the reaction product, so care must be taken.
- a solvent of about 40 to 50 mL may be used.
- the reaction solution is filtered and the precipitate is filtered off.
- the white precipitate is suspended in a methanol / water mixture (1: 1), and then a saturated sodium bicarbonate aqueous solution is suspended in this precipitate. If it is added so that it becomes a large square IJ, 2_ (4,1hydroxyphenyl) 1-6-methoxyimidazo [1,2,2-a] pyridine is liberated and precipitation occurs.
- 2- (4, -hydroxyphenyl) -6-methoxyimidazo [1,2-a] pyridine which is the target product of this step, can be obtained as crystals. it can.
- the amount of the water / methanol mixed solution is not particularly limited as long as it is sufficient for the reaction. However, if it is too much, caution is required because it will hinder the precipitation of crystals. For example, if 2-bromo-4'-hydroxyacetophenone equivalent to lOmmol is used, a water / methanol mixture of about 40 to: OOmL may be used.
- the amount of sodium bicarbonate is not particularly limited if it is a large excess with respect to the precipitate as a reaction substrate. For example, in the case of reacting under the above conditions, about 25 mL of saturated sodium bicarbonate Add an aqueous solution to the reaction solution.
- 1, step 7 1,3_propanedionomonomononaphthenosenosulfonate f as an auxiliary material.
- f row literature Abderrahim Bouzide and Gilles Sauv e, Organic Letters, 2002, 4 (14), ⁇ ⁇ 2329_2332 ⁇
- Fig. 1, step 6 it may be used in a molar ratio of about 2-fold with respect to 2- (4'-hydroxyphenyl) -6-methoxyimidazo [1, 2_a] pyridine, which is a reaction substrate.
- triphenylphosphine and diisopropylazodicarboxylate are the same as those of 1,3_propanediol monoparatoluene sulfonate, which is typically an auxiliary material, according to general Mitsunobu reaction conditions. About a mole may be used.
- the compound in which the 6-position is a hydroxy substituent is obtained by adding boron tribromide or the like to 2_ (4'-hydroxyphenyl) _6-methoxyimidazo [1,2_a] pyridine obtained in Step 5 above. After the demethylation reaction is performed, the 6-position hydroxyl group is protected with a tetrahydropyranyl group, etc., and then the reaction in Step 7 is performed, and finally the 6-position protection group is deprotected. That power S.
- the H 180 concentrated water containing [ 18 F] fluoride ions is passed through an anion exchange column.
- Liquid is adsorbed and collected on the column, and separated from H 180 concentrated water. Then the
- a mixture containing a phase transfer catalyst, [ 18 F] fluoride ions and potassium ions is obtained by flowing potassium carbonate solution through the column to elute the [ 18 F] fluoride ions and adding a phase transfer catalyst to dryness. Can be obtained.
- phase transfer catalyst various compounds having a property of forming an inclusion with [ 18 F] fluoride ion can be used. Specifically, various compounds used in the production of radioactive fluorine-labeled organic compounds can be used, and 18-crown-6-ether and other various aminopolyethers can be used. . As the most preferable mode, Talibufix 222 (trade name, manufactured by Merck & Co., Inc.) can be used.
- the reaction conditions can be set according to the conditions in other radiofluorinated compounds such as 2- [ 18 F] fluoro-2-deoxy-D-glucose.
- the reaction solution can be used under the condition of 90 to 130 ° C for 5 to 10 minutes.
- radiohalogen-labeled compounds can be performed by appropriately selecting a labeling precursor and a radiohalogen to be used, and giving reaction conditions according to known methods.
- a labeling precursor and a radiohalogen for example, the synthesis of 2— [4, — (3 ,, — [ 12 3 ⁇ 4 odopropoxy) phenyl] — 6-methoxymidazo [1, 2—a] pyridine can be synthesized using 2- [4 ′ 3 "- black port propoxy) Hue sulfonyl] - 6-methoxy-imidazo [1, 2 _a] Yore ,, acetone or methanol in a solvent of pyridine, be obtained by metathesis reaction with Na [123 I] it can.
- the diagnostic agent according to the present invention is water or physiological saline or Ringer's solution in which the radiohalogen-labeled compound according to the present invention is adjusted to an appropriate pH as required. It can be prepared as a liquid blended with the above. In this case, the concentration of the present compound needs to be lower than the concentration at which the stability of the blended present compound is obtained. The dose of the compound should be sufficient to image the distribution of the administered drug There is no particular limitation as long as the concentration is high.
- NMR apparatus used JNM— ECP— 500 (manufactured by JEOL Ltd.)
- reaction solution was concentrated, and 57 mL of chloroform and 57 mL of methanol were added thereto for repulping, followed by filtration to separate the precipitate and the filtrate.
- the precipitate was washed with 114 mL of a black form-methanol mixture (1: 1), and the filtrates were combined and concentrated under reduced pressure.
- NMR apparatus used JNM—GSX—270 (manufactured by JEOL Ltd.)
- NMR measurement results (internal standard substance: tetramethylsilane) were as follows.
- NMR apparatus used JNM— ECP— 500 (manufactured by JEOL Ltd.)
- NMR apparatus used JNM— ECP— 500 (manufactured by JEOL Ltd.)
- NMR apparatus used JNM— ECP— 500 (manufactured by JEOL Ltd.)
- NMR apparatus used JNM- ECP-500 (manufactured by JEOL Ltd.)
- Detector Bioimaging analyzer, BAS-2500 (Type: BAS-2500, manufactured by Fuji Photo Film Co., Ltd.)
- NMR apparatus used JNM- ECP-500 (manufactured by JEOL Ltd.)
- TLC plate Silica Gel 60 F (product name, manufactured by Merck)
- amyloid affinity of the compound of the present invention was evaluated by the following in vitro binding test.
- amyloid suspension After dissolution, the mixture was shaken at 37 ° C. for 62 to 72 hours to obtain a lmg / mL aggregated AiS suspension (hereinafter referred to as amyloid suspension in this example).
- Table 3 shows the IC value of each evaluation compound.
- Compounds 1-3 are all less than 100 IC
- Amyloid aggregated A higher than Congo Red and Thioflavin ⁇ ⁇
- logP The partition coefficient by HPLC
- each evaluation compound shown in Table 5 was dissolved in methanol containing 10% dimethyl sulfoxide so as to have a concentration of 1 mg / mL to prepare a sample solution.
- the sample solution 1 was subjected to HPLC analysis under the following conditions.
- the solvent elution time (t) and the compound elution time (t) were subjected to HPLC analysis under the following conditions.
- the retention factor (hereinafter referred to as “retention factor”) of each evaluation compound is calculated from the formula (3).
- the y intercept was estimated. Using this value, the logP value and logP value are between pH 7.2 and 7.
- the logP value for the compound was determined.
- Each 0.05 mL of the solution dissolved in the solution was administered to the rats through the tail vein under thiopental anesthesia.
- blood was collected from the abdominal aorta and the brain was collected, and the radioactivity in the brain was measured using the Autoll 'gamma system (form: ARC_ 301B, manufactured by Aloka).
- the brain mass was further measured.
- the amount of radioactivity was measured in the same manner for 0.05 mL of a 1000-fold diluted solution (hereinafter referred to as “B” in this example).
- the radioactivity distribution rate (% 107 ⁇ ) per unit weight to the brain at each dissection time point was calculated from the following formula (5). The experiment was performed using three animals at each time point.
- amyloid suspension a lmg / mL aggregated Aj3 suspension (hereinafter referred to as amyloid suspension in this example) was obtained.
- Fig. 9 shows images of autoradiogram and thioflavin T staining in brain sections of rats injected with amyloid in the brain.
- the amygdaloid nucleus on the side injected with the amyloid suspension had a clear radioactivity accumulation and a good image with little non-specific accumulation at other sites.
- the results of thioflavin T staining at the radioactive accumulation site confirmed that amyloid was present at the site where accumulation was observed.
- no significant radioactivity accumulation was confirmed in the amygdaloid nucleus on the side injected with phosphate buffered saline as compared with other sites.
- Compound 4 has the ability to accumulate in brain amyloid and has the ability to visualize brain amyloid.
- Each sample was added to the test plate at a maximum dose of 1250 xg / plate for Compound 1, 7 doses (common ratio 4), and 5000 z gZ plates for Compound 2 and Compound 3. The highest dose was 7 doses (public ratio 3).
- the test substance and the test strain (TA98 or TA100), or the test substance, S9mix and the test strain were mixed, and then layered on the medium on the test plate using soft agar and cultured at 37 ° C for 48 hours. Judgment was made by counting the number of revertant colonies in the plate after culturing, and when the number of revertant colonies showed a value more than twice that of the negative control and further increased depending on the concentration. Positive.
- Example 1 Compound 1 Negative Negative Negative Negative Negative Example 1 3 Compound 2 Negative Negative Negative Example 1 4 Compound 3 Negative Negative Negative Negative Industrial applicability
- the compounds according to the present invention can be used in the field of diagnostic agents.
- FIG. 1 Synthesis scheme of 6-methoxy-2- [4 '-(3 "-paratoluenesulfonyloxypropoxy) phenino] imidazo [1,2-a] pyridine.
- FIG. 2 Synthesis scheme of 2- [4 '-(3 "fluoropropoxy) phenyl] 6-methoxyimidazo [1,2-a] pyridine (non-radioactive fluorinated product).
- FIG. 8 Synthesis scheme of [ 12 3 ⁇ 4_2_ (4'-hydroxyphenyl) _6_ odoimidazo [1, 2_a] pyridine.
- FIG. 9 (a) Autoradiogram in brain section 30 minutes after administration of Compound 4 and (b) Fluorescent micrograph of thioflavine T-stained sample (enlarged display of amyloid suspension administration site.)
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Optics & Photonics (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07767329.1A EP2042501B1 (en) | 2006-06-21 | 2007-06-21 | Compound having affinity for amyloid |
JP2008522509A JP5247442B2 (ja) | 2006-06-21 | 2007-06-21 | 新規アミロイド親和性化合物 |
AU2007261985A AU2007261985B2 (en) | 2006-06-21 | 2007-06-21 | Novel compound having affinity for amyloid |
NZ574164A NZ574164A (en) | 2006-06-21 | 2007-06-21 | Novel compound having affinity for amyloid |
CN2007800298930A CN101501033B (zh) | 2006-06-21 | 2007-06-21 | 对淀粉状蛋白具有亲和性的化合物 |
CA002655826A CA2655826A1 (en) | 2006-06-21 | 2007-06-21 | Novel compound having affinity for amyloid |
US12/308,715 US8277777B2 (en) | 2006-06-21 | 2007-06-21 | Compound having affinity for amyloid |
ES07767329.1T ES2629768T3 (es) | 2006-06-21 | 2007-06-21 | Compuesto con afinidad por amiloide |
IL196046A IL196046A0 (en) | 2006-06-21 | 2008-12-18 | Novel compound having affinity for amyloid |
NO20090233A NO20090233L (no) | 2006-06-21 | 2009-01-14 | Ny sammensetning som har affinitet for amyloid |
HK09111320.9A HK1133254A1 (en) | 2006-06-21 | 2009-12-03 | Compound having affinity for amyloid |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US80535606P | 2006-06-21 | 2006-06-21 | |
US60/805356 | 2006-06-21 | ||
JP2006-188034 | 2006-07-07 | ||
JP2006188034 | 2006-07-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007148755A1 true WO2007148755A1 (ja) | 2007-12-27 |
Family
ID=38833493
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2007/062503 WO2007148755A1 (ja) | 2006-06-21 | 2007-06-21 | 新規アミロイド親和性化合物 |
Country Status (10)
Country | Link |
---|---|
US (1) | US8277777B2 (ja) |
EP (1) | EP2042501B1 (ja) |
KR (1) | KR20090025282A (ja) |
CN (1) | CN101501033B (ja) |
AU (1) | AU2007261985B2 (ja) |
CA (1) | CA2655826A1 (ja) |
HK (1) | HK1133254A1 (ja) |
IL (1) | IL196046A0 (ja) |
NO (1) | NO20090233L (ja) |
WO (1) | WO2007148755A1 (ja) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009054497A1 (ja) * | 2007-10-26 | 2009-04-30 | Nihon Medi-Physics Co., Ltd. | 新規アミロイド親和性化合物 |
EP2218464A1 (en) * | 2009-02-11 | 2010-08-18 | Technische Universität München | Compounds for non-invasive measurement of aggregates of amyloid peptides |
JP2010241788A (ja) * | 2009-04-09 | 2010-10-28 | Industry-Univ Cooperation Foundation Sogang Univ | 退行性脳疾患の診断用または治療用の医薬組成物 |
WO2012176587A1 (ja) * | 2011-06-24 | 2012-12-27 | 日本メジフィジックス株式会社 | 新規アミロイド親和性化合物 |
JP2016520046A (ja) * | 2013-04-29 | 2016-07-11 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 2−フェニル又は2−ヘタリールイミダゾール[1,2−a]ピリジン誘導体 |
JP2017503012A (ja) * | 2013-12-20 | 2017-01-26 | ベイジン ズィボォ バイオメディカル テクノロジー カンパニー、リミテッド | フェニルベンジルエーテル系誘導体及びその調製方法と応用 |
JP2017529340A (ja) * | 2014-08-29 | 2017-10-05 | シーエイチディーアイ ファウンデーション,インコーポレーテッド | ハンチントンタンパク質のイメージング用プローブ |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200803903A (en) * | 2006-04-28 | 2008-01-16 | Nihon Mediphysics Co Ltd | Novel compound having affinity to amyloid |
ATE535527T1 (de) | 2006-05-19 | 2011-12-15 | Nihon Mediphysics Co Ltd | Verbindung mit affinität zu amyloid |
TW200823211A (en) | 2006-11-30 | 2008-06-01 | Nihon Mediphysics Co Ltd | Novel compound having affinity for amyloid |
TW200918102A (en) * | 2007-10-24 | 2009-05-01 | Nihon Mediphysics Co Ltd | Novel compound having affinity for amyloid |
US9926316B2 (en) * | 2016-03-03 | 2018-03-27 | The Cleveland Clinic Foundation | Antitumor derivatives for differentiation therapy |
CN108822105A (zh) * | 2018-08-14 | 2018-11-16 | 河南师范大学 | 一种由乙苯类化合物合成2-芳基咪唑并[1,2-a]吡啶类化合物的方法 |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6391391A (ja) * | 1986-09-22 | 1988-04-22 | オーソ・フアーマシユーチカル・コーポレーシヨン | 2−または3−アリール置換イミダゾ[1,2−a]ビリジン |
WO2001074815A2 (en) * | 2000-03-31 | 2001-10-11 | Ortho Mcneil Pharmaceutical, Inc. | Phenyl-substituted imidazopyridines |
WO2001074813A2 (en) * | 2000-03-31 | 2001-10-11 | Ortho Mcneil Pharmaceutical, Inc. | METHOD FOR USING 2- OR 3-ARYL SUBSTITUTED IMIDAZO[1,2-a] PYRIDINES AS H3 ANTAGONISTS |
JP2002523383A (ja) | 1998-08-20 | 2002-07-30 | リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア | βアミロイド斑及び神経原線維変化の標識方法 |
WO2003106439A1 (ja) | 2002-06-12 | 2003-12-24 | 株式会社ビーエフ研究所 | アミロイド蓄積性疾患の画像診断プローブ化合物、老人斑/びまん性老人斑染色用化合物、ならびにアミロイド蓄積性疾患の治療薬 |
JP2004506723A (ja) | 2000-08-24 | 2004-03-04 | ユニバーシティー オブ ピッツバーグ | アルツハイマー病の生前診断ならびにアミロイド沈着物のインビボ画像化および予防に用いるためのチオフラビン誘導体 |
JP2004506633A (ja) * | 2000-08-16 | 2004-03-04 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | 新規β−アミロイド阻害剤、その製造方法及び医薬組成物としての使用 |
JP2005504055A (ja) | 2001-08-27 | 2005-02-10 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | スチルベン誘導体、およびアミロイド斑の結合および画像化のためのその使用 |
JP2005512945A (ja) | 2001-04-23 | 2005-05-12 | ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア | アミロイド斑凝集阻害剤および診断用造影剤 |
JP2005526749A (ja) * | 2002-03-06 | 2005-09-08 | ノバルティス アクチエンゲゼルシャフト | バイオマーカーとして有用なクマリン |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4791117A (en) | 1986-09-22 | 1988-12-13 | Ortho Pharmaceutical Corporation | 2- or 3-aryl substituted imidazo[1,2-a]pyridines and their use as calcium channel blockers |
US4833149A (en) | 1986-09-22 | 1989-05-23 | Ortho Pharmaceutical Corporation | 2- or 3-aryl substituted imidazo[1,2-a]pyridines |
US4871745A (en) * | 1986-09-22 | 1989-10-03 | Ortho Pharmaceutical Corporation | 2- or 3-aryl substituted imidazo(1,2-A)pyridines and their use as antisecretory agents |
EP0859642A2 (en) | 1995-10-17 | 1998-08-26 | G.D. Searle & Co. | Method of detecting cyclooxygenase-2 |
US6812327B1 (en) | 1996-10-25 | 2004-11-02 | Human Genome Sciences, Inc. | Neutrokine-alpha polypeptides |
JP4025468B2 (ja) | 1999-07-29 | 2007-12-19 | 三井化学株式会社 | 有機電界発光素子 |
US20010051632A1 (en) | 2000-03-31 | 2001-12-13 | Wenying Chai | Phenyl-substituted indolizines and tetrahydroindolizines |
US6514969B2 (en) | 2000-08-16 | 2003-02-04 | Boehringer Ingelheim Pharma Kg | β-amyloid inhibitors, processes for preparing them, and their use in pharmaceutical compositions |
MXPA03007595A (es) | 2001-02-26 | 2003-12-04 | Bristol Myers Squibb Pharma Co | Analogos de acido ascorbico para metalorradiofarmaceuticos. |
US6596731B2 (en) | 2001-03-27 | 2003-07-22 | Hoffmann-La Roche Inc. | Substituted imidazo[1,2-A] pyridine derivatives |
EP1356827A1 (en) | 2002-04-24 | 2003-10-29 | Mallinckrodt Inc. | Method for obtaining a 2-18F-fluor-2-deoxy-D-glucose (18F-FDG)-solution |
JP2006505610A (ja) | 2002-11-05 | 2006-02-16 | イヨン ベアム アプリカスィヨン エッス.アー. | 18−f標識放射性製剤の安定化 |
GB0229695D0 (en) | 2002-12-20 | 2003-01-29 | Amersham Plc | Solid-phase preparation of 18F-labelled amino acids |
NZ548098A (en) | 2003-12-31 | 2010-05-28 | Schering Plough Ltd | Control of parasites in animals by the use of imidazo[1,2-b]pyridazine derivatives |
US20070031328A1 (en) * | 2005-06-24 | 2007-02-08 | Kung Hank F | Radiolabeled-pegylation of ligands for use as imaging agents |
US20080219922A1 (en) * | 2005-09-12 | 2008-09-11 | Goodman Mark M | Alzheimer's Disease Imaging Agents |
ATE535527T1 (de) | 2006-05-19 | 2011-12-15 | Nihon Mediphysics Co Ltd | Verbindung mit affinität zu amyloid |
TW200918102A (en) | 2007-10-24 | 2009-05-01 | Nihon Mediphysics Co Ltd | Novel compound having affinity for amyloid |
CA2704027A1 (en) | 2007-10-26 | 2009-04-30 | Nihon Medi-Physics Co., Ltd. | Novel compound having affinity for amyloid |
EP2216050A4 (en) | 2007-10-30 | 2012-11-21 | Nihon Mediphysics Co Ltd | USE OF NEW COMPOUNDS WITH AMYLOID AFFINITY AND METHOD OF MANUFACTURING THEREOF |
-
2007
- 2007-06-21 KR KR1020087031662A patent/KR20090025282A/ko not_active Application Discontinuation
- 2007-06-21 EP EP07767329.1A patent/EP2042501B1/en active Active
- 2007-06-21 CN CN2007800298930A patent/CN101501033B/zh active Active
- 2007-06-21 WO PCT/JP2007/062503 patent/WO2007148755A1/ja active Application Filing
- 2007-06-21 AU AU2007261985A patent/AU2007261985B2/en not_active Expired - Fee Related
- 2007-06-21 CA CA002655826A patent/CA2655826A1/en not_active Abandoned
- 2007-06-21 US US12/308,715 patent/US8277777B2/en active Active
-
2008
- 2008-12-18 IL IL196046A patent/IL196046A0/en unknown
-
2009
- 2009-01-14 NO NO20090233A patent/NO20090233L/no not_active Application Discontinuation
- 2009-12-03 HK HK09111320.9A patent/HK1133254A1/xx unknown
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6391391A (ja) * | 1986-09-22 | 1988-04-22 | オーソ・フアーマシユーチカル・コーポレーシヨン | 2−または3−アリール置換イミダゾ[1,2−a]ビリジン |
JP2002523383A (ja) | 1998-08-20 | 2002-07-30 | リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア | βアミロイド斑及び神経原線維変化の標識方法 |
WO2001074815A2 (en) * | 2000-03-31 | 2001-10-11 | Ortho Mcneil Pharmaceutical, Inc. | Phenyl-substituted imidazopyridines |
WO2001074813A2 (en) * | 2000-03-31 | 2001-10-11 | Ortho Mcneil Pharmaceutical, Inc. | METHOD FOR USING 2- OR 3-ARYL SUBSTITUTED IMIDAZO[1,2-a] PYRIDINES AS H3 ANTAGONISTS |
JP2004506633A (ja) * | 2000-08-16 | 2004-03-04 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | 新規β−アミロイド阻害剤、その製造方法及び医薬組成物としての使用 |
JP2004506723A (ja) | 2000-08-24 | 2004-03-04 | ユニバーシティー オブ ピッツバーグ | アルツハイマー病の生前診断ならびにアミロイド沈着物のインビボ画像化および予防に用いるためのチオフラビン誘導体 |
JP2005512945A (ja) | 2001-04-23 | 2005-05-12 | ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア | アミロイド斑凝集阻害剤および診断用造影剤 |
JP2005504055A (ja) | 2001-08-27 | 2005-02-10 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | スチルベン誘導体、およびアミロイド斑の結合および画像化のためのその使用 |
JP2005526749A (ja) * | 2002-03-06 | 2005-09-08 | ノバルティス アクチエンゲゼルシャフト | バイオマーカーとして有用なクマリン |
WO2003106439A1 (ja) | 2002-06-12 | 2003-12-24 | 株式会社ビーエフ研究所 | アミロイド蓄積性疾患の画像診断プローブ化合物、老人斑/びまん性老人斑染色用化合物、ならびにアミロイド蓄積性疾患の治療薬 |
Non-Patent Citations (27)
Title |
---|
ABDERRAHIM BOUZIDE; GILLES SAUVE, ORGANIC LETTERS, vol. 4, no. 14, 2002, pages 2329 - 2332 |
DOUGLAS D. DISCHINO ET AL., J. NUCL. MED., vol. 24, 1983, pages 1030 - 1038 |
ERIC D. AGDEPPA ET AL.: "2-Dialkylamino-6-Acylmalononitrile Substituted Naphthalenes (DDNP Analogs): Novel Diagnostic and Therapeutic Tools in Alzheimer's Disease.", MOLECULAR IMAGING AND BIOLOGY, vol. 5, 2003, pages 404 - 417 |
FRANCO LOMBARDO ET AL., J. MED. CHEM., vol. 43, 2000, pages 2922 - 2927 |
FURUMOTO Y ET AL.: "11c] BF-227: A New 11C-Labeled 2-Ethenylbenzoxazole Derivative for Amyloid-ß Plaques Imaging", EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol. 32, no. 1, 2005, pages 759 |
G. MCKHANN ET AL.: "Clinical diagnosis of Alzheimer's disease: Report of the NINLDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease", NEUROLOGY, vol. 34, 1984, pages 939 - 944, XP000671871 |
H. F. KUNG ET AL., J. AM. CHEM. SOC., vol. 123, 2001, pages 12740 - 12741 |
H. F. KUNG ET AL.: "Novel Stilbenes as Probes for amyloid plaques", J. AMERICAN CHEMICAL SOCIETY, vol. 123, 2001, pages 12740 - 12741 |
J. A. HARDY; G. A. HIGGINS: "Alzheimer's Disease: The Amyloid Cascade Hypothesis", SCIENCE, vol. 256, 1992, pages 184 - 185 |
JOSEPH G. LOMBARDINO, JOURNAL OF MEDICINAL CHEMISTRY, vol. 24, 1981, pages 39 - 42 |
KING, L. CARROLL; OSTRUM, G. KENNETH, JOURNAL OF ORGANIC CHEMISTRY, vol. 29, no. 12, 1964, pages 3459 - 3461 |
MASAHIRO ONO ET AL., NUCLEAR MEDICINE AND BIOLOGY, vol. 30, 2003, pages 565 - 571 |
MASAHIRO ONO ET AL.: "11C-labeled stilbene derivatives as Aß-aggregate-specific PET imaging agents for Alzheimer's disease", NUCLEAR MEDICINE AND BIOLOGY, vol. 30, 2003, pages 565 - 571, XP004444174, DOI: doi:10.1016/S0969-8051(03)00049-0 |
NAIKI, H. ET AL., LABORATORY INVESTIGATION, vol. 74, 1996, pages 374 - 383 |
NICOLAAS P. L. G. VERHOEFF ET AL.: "In-Vivo Imaging of Alzheimer Disease ß-Amyloid With [11C]SB-13 PET.", AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, vol. 12, 2004, pages 584 - 595, XP009121906 |
SANFILIPPO P.J. ET AL.: "Synthesis of (Aryloxy) alkylamides. 2. Novel Imidazo-fused Heterocycles with Calcium Channel Blocking and Local Anesthetic Activity", JOURNAL OF MEDICINAL CHEMISTRY, vol. 31, no. 11, 1988, pages 2221 - 2227, XP002182515 * |
See also references of EP2042501A4 |
SHAH C. ET AL.: "Novel Human Histamine H3 Receptor Antagonists", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 12, no. 22, 2002, pages 3309 - 3312, XP002353596 * |
W. E. KLUNK ET AL.: "Imaging brain amyloid in Alzheumer's disease with Pittsburgh Compound-B.", ANN. NEUROL., vol. 55, 2004, pages 306 - 319, XP008031485, DOI: doi:10.1002/ana.20009 |
WANG, Y. ET AL., J. LABELLED COMPOUNDS RADIOPHARMACEUT., vol. 44, 2001, pages 239 |
WANG. Y. ET AL., J. LABELLED COMPOUNDS RADIOPHARMACEUT., vol. 44, 2001, pages 239 |
Z.-P. ZHUANG ET AL.: "Radioiodinated Styrylbenzenes and Thioflavins as Probes for Amyloid Aggregates", J. MED. CHEM., vol. 44, 2001, pages 1905 - 1914, XP002410969, DOI: doi:10.1021/jm010045q |
ZHI-PING ZHUANG ET AL., J. MED. CHEM., vol. 46, 2003, pages 237 - 243 |
ZHI-PING ZHUANG ET AL., NUCLEAR MEDICINE AND BIOLOGY, vol. 28, 2001, pages 887 - 894 |
ZHI-PING ZHUANG ET AL.: "IBOX(2-(4' -dimethylaminophenyl)-6-iodobenzoxazole): a ligand for imaging amyloid plaques in the brain", NUCLEAR MEDICINE AND BIOLOGY, vol. 28, 2001, pages 887 - 894, XP002386398 |
ZHI-PING ZHUANG ET AL.: "Structure-Activity Relationship of Imidazo[1,2- a]pyridines as Ligands for Detecting ß-Amyloid Plaques in the Brain", J. MED. CHEM, vol. 46, 2003, pages 237 - 243, XP002446716, DOI: doi:10.1021/jm020351j |
ZHUANG, Z. P. ET AL., J. MED. CHEM., vol. 46, 2003, pages 237 |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5313158B2 (ja) * | 2007-10-26 | 2013-10-09 | 日本メジフィジックス株式会社 | 新規アミロイド親和性化合物 |
WO2009054497A1 (ja) * | 2007-10-26 | 2009-04-30 | Nihon Medi-Physics Co., Ltd. | 新規アミロイド親和性化合物 |
US8399672B2 (en) | 2007-10-26 | 2013-03-19 | Nihon Medi-Physics Co., Ltd. | Compound having affinity for amyloid |
EP2218464A1 (en) * | 2009-02-11 | 2010-08-18 | Technische Universität München | Compounds for non-invasive measurement of aggregates of amyloid peptides |
JP2010241788A (ja) * | 2009-04-09 | 2010-10-28 | Industry-Univ Cooperation Foundation Sogang Univ | 退行性脳疾患の診断用または治療用の医薬組成物 |
WO2012176587A1 (ja) * | 2011-06-24 | 2012-12-27 | 日本メジフィジックス株式会社 | 新規アミロイド親和性化合物 |
JP5167436B2 (ja) * | 2011-06-24 | 2013-03-21 | 日本メジフィジックス株式会社 | 新規アミロイド親和性化合物 |
US9211350B2 (en) | 2011-06-24 | 2015-12-15 | Nihon Medi-Physics Co., Ltd. | Compound with amyloid affinity |
JP2016520046A (ja) * | 2013-04-29 | 2016-07-11 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 2−フェニル又は2−ヘタリールイミダゾール[1,2−a]ピリジン誘導体 |
US10975073B2 (en) | 2013-04-29 | 2021-04-13 | Hoffmann-La Roche Inc. | Imaging methods using 2-hetaryl imidazol[1,2-a]pyridine derivatives |
US11358962B2 (en) | 2013-04-29 | 2022-06-14 | Hoffmann-La Roche Inc. | 2-hetaryl imidazol[1,2-a]pyridine derivatives |
JP2017503012A (ja) * | 2013-12-20 | 2017-01-26 | ベイジン ズィボォ バイオメディカル テクノロジー カンパニー、リミテッド | フェニルベンジルエーテル系誘導体及びその調製方法と応用 |
JP2017529340A (ja) * | 2014-08-29 | 2017-10-05 | シーエイチディーアイ ファウンデーション,インコーポレーテッド | ハンチントンタンパク質のイメージング用プローブ |
Also Published As
Publication number | Publication date |
---|---|
CN101501033A (zh) | 2009-08-05 |
CN101501033B (zh) | 2012-08-01 |
CA2655826A1 (en) | 2007-12-27 |
AU2007261985B2 (en) | 2012-04-19 |
KR20090025282A (ko) | 2009-03-10 |
US20100092387A1 (en) | 2010-04-15 |
EP2042501A4 (en) | 2012-11-21 |
AU2007261985A1 (en) | 2007-12-27 |
HK1133254A1 (en) | 2010-03-19 |
NO20090233L (no) | 2009-02-11 |
US8277777B2 (en) | 2012-10-02 |
IL196046A0 (en) | 2009-09-01 |
EP2042501A1 (en) | 2009-04-01 |
EP2042501B1 (en) | 2017-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007148755A1 (ja) | 新規アミロイド親和性化合物 | |
JP5313158B2 (ja) | 新規アミロイド親和性化合物 | |
JP5238496B2 (ja) | 新規アミロイド親和性化合物 | |
JP5048655B2 (ja) | 新規アミロイド親和性化合物 | |
JPWO2009054496A1 (ja) | 新規アミロイド親和性化合物 | |
JP5180838B2 (ja) | 新規アミロイド親和性化合物 | |
JPWO2008059714A1 (ja) | 新規アミロイド親和性化合物 | |
KR20100089858A (ko) | 신규 아밀로이드 친화성 화합물의 사용 및 제조 방법 | |
EP2216052A1 (en) | Use of novel compound having affinity for amyloid, and process for production of the same | |
KR20100094478A (ko) | 신규 아밀로이드 친화성 화합물의 사용 및 제조 방법 | |
JP5247442B2 (ja) | 新規アミロイド親和性化合物 | |
JP2009120590A (ja) | 新規アミロイド親和性化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780029893.0 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07767329 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008522509 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 196046 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2655826 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020087031662 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 574164 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007261985 Country of ref document: AU |
|
REEP | Request for entry into the european phase |
Ref document number: 2007767329 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 371/DELNP/2009 Country of ref document: IN Ref document number: 2007767329 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2007261985 Country of ref document: AU Date of ref document: 20070621 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12308715 Country of ref document: US |